Amneal Pharmaceuticals, Inc. (AMRX) — Financial statements
Income statement, balance sheet, and cash flow for Amneal Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3,019↑8.0% | 2,794↑16.7% | 2,394↑8.2% | 2,212↑5.7% | 2,094 | |
| Cost of Revenue | 1,883↑6.2% | 1,774↑15.9% | 1,530↑7.7% | 1,421↑7.3% | 1,325 | |
| Gross Profit | 1,136↑11.3% | 1,020↑18.1% | 864↑9.1% | 791↑2.9% | 769 | |
| Operating Expenses | ||||||
| R&D Expenses | 186↓2.4% | 191↓2.1% | 195↓6.7% | 209↓0.4% | 210 | |
| General & Administrative Expenses | 0.00↓100.0% | 442↑5.9% | 417↑9.0% | 383 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 34↑177.4% | 12↓26.2% | 17 | 0.00 | |
| SG&A Expenses | 527↑10.6% | 476↑10.9% | 430↑7.5% | 400↑9.4% | 366 | |
| Other Expenses | 0.00↓100.0% | 104↑196.4% | 35↓87.4% | 278↑575.0% | 41 | |
| Operating Expenses | 713↓7.5% | 771↑16.9% | 659↓25.6% | 886↑43.8% | 616 | |
| Total Costs & Expenses | 2,596↑2.0% | 2,545↑16.2% | 2,189↓5.1% | 2,307↑18.9% | 1,941 | |
| Operating Results | ||||||
| Operating Income | 423↑69.7% | 249↑22.0% | 204↑315.3% | -95↓162.2% | 153 | |
| Depreciation & Amortization | 224↓5.3% | 236↑3.0% | 229↓4.5% | 240↑2.9% | 233 | |
| EBITDA | 604↑37.3% | 440↓12.2% | 501↑13.8% | 440↑9.8% | 401 | |
| EBIT | 380↑86.8% | 204↓25.0% | 271↑35.7% | 200↑19.3% | 168 | |
| Interest & Other Income | ||||||
| Net Interest Income | -241↑6.8% | -259↓22.8% | -211↓32.7% | -159↓16.4% | -136 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 158 | 0.00 | |
| Interest Expense | 241↓6.8% | 259↑22.8% | 211↑33.0% | 158↑16.2% | 136 | |
| Non-Operating Income | 43↓6.5% | 46↑168.3% | -67↑77.3% | -295↓1869.7% | -15 | |
| Other Income / Expenses | -284↑6.7% | -304↓24.4% | -245↓59.7% | -153↓26.2% | -121 | |
| Income Before Tax | 139↑353.0% | -55↓36.6% | -40↑83.8% | -248↓891.1% | 31 | |
| Income Tax Expense | 11↓40.2% | 19↑123.2% | 8↑26.9% | 7↓40.5% | 11 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 128↑273.2% | -74↓51.6% | -49↑80.9% | -255↓1363.2% | 20 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 72↑161.6% | -117↓39.2% | -84↑35.4% | -130↓1323.5% | 11 | |
| Bottom-Line Net Income | 72↑161.6% | -117↓39.2% | -84↑35.4% | -130↓1323.5% | 11 | |
| EPS (Basic) | 0.23↑160.5% | -0.38↑20.8% | -0.48↑44.2% | -0.86↓1328.6% | 0.07 | |
| EPS (Diluted) | 0.22↑157.9% | -0.38↑20.8% | -0.48↑44.2% | -0.86↓1328.6% | 0.07 | |
| Weighted Average Shares | 313↑1.4% | 309↑76.6% | 175↑15.9% | 151↑1.4% | 149 | |
| Weighted Average Diluted Shares | 325↑5.1% | 309↑75.4% | 176↑16.7% | 151↓0.6% | 152 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.